A. A single cycle of multi-agent chemotherapy B. Induction chemotherapy followed by allogeneic stem cell transplant for every patient C. Induction chemotherapy followed by intensification and then maintenance therapy D. Induction chemotherapy followed by maintenance therapy E. Unsure

A. Constipation and syndrome of inappropriate antidiuretic hormone secretion; minimal neuropathy B. Constipation and neuropathy; no myelosuppression C. Only myelosuppression; no constipation or neuropathy D. Constipation, myelosuppression, and neuropathy E. Unsure

A. Combination therapy with cyclophosphamide, doxorubicin, and prednisone for non-Hodgkin lymphoma B. Use as an alternative to conventional vincristine formulation for grade 3 or worse neurotoxicity C. Use in induction therapy for acute lymphoblastic leukemia (ALL) with corticosteroids and L-asparaginase D. Use as salvage therapy for relapsed ALL patients with 2 or more prior anti-leukemic therapies E. Unsure

A. Binding and subsequent endocytosis of the anti-CD22-antigen antibody-drug conjugate that releases calicheamicin resulting in DNA strand breaks B. Blunting the activity of PD-1 receptors thereby restoring antitumor T-cell activity C. Reprogramming of genetically modified autologous T-cells to recognize and attack CD19-positive acute lymphoblastic leukemia cells D. Bi-specific CD19-directed CD3 T-cell engager that activates endogenous T-cells by connecting CD3 in the T-cell receptor complex with CD19 on malignant B-cells E. Unsure

A. Obtain prior authorization for treatment B. Monitor at bedside for infusion-related toxicity during administration C. Perform surveillance for changes in hepatic function and avoid use of concomitant hepatotoxic drugs D. Assess appropriateness for hematopoietic stem cell transplant on the basis of donor availability E. Unsure

A. Patients with T-cell ALL B. Patients with ALL who are older than 50 years of age C. Patients of any age who are newly diagnosed with ALL D. Patients aged 25 years or younger with B-cell ALL that has relapsed following conventional treatment E. Unsure

A. Infusion-related reaction B. Cytokine release syndrome C. Secondary malignancy D. Hepatic veno-occlusive disease following hematopoietic stem cell transplant E. Unsure

A. Vincristine sulfate liposomal injection B. Blinatumomab C. Inotuzumab ozogamicin D. Tisagenlecleucel E. Unsure